
Amber D. Steele
Examiner (ID: 2430, Phone: (571)272-5538 , Office: P/1676 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1654, 1639, 1658, 1676 |
| Total Applications | 1302 |
| Issued Applications | 628 |
| Pending Applications | 166 |
| Abandoned Applications | 538 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15293573
[patent_doc_number] => 20190389922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => PEPTIDES FOR ANGIOGENIC THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/465808
[patent_app_country] => US
[patent_app_date] => 2019-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24368
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465808
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/465808 | Peptides for angiogenic therapy | Jan 24, 2019 | Issued |
Array
(
[id] => 14581805
[patent_doc_number] => 20190218511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => METHODS AND COMPOSITIONS FOR TARGETING PROGENITOR CELL LINES
[patent_app_type] => utility
[patent_app_number] => 16/254086
[patent_app_country] => US
[patent_app_date] => 2019-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16254086
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/254086 | METHODS AND COMPOSITIONS FOR TARGETING PROGENITOR CELL LINES | Jan 21, 2019 | Abandoned |
Array
(
[id] => 16778033
[patent_doc_number] => 20210115111
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => USE OF A PEPTIDE DERIVED FROM THE HUMAN PROTEIN NTIMP3 IN THE TREATMENT OF DIABETIC NEPHROPATHY
[patent_app_type] => utility
[patent_app_number] => 16/964071
[patent_app_country] => US
[patent_app_date] => 2019-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5482
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964071
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/964071 | USE OF A PEPTIDE DERIVED FROM THE HUMAN PROTEIN NTIMP3 IN THE TREATMENT OF DIABETIC NEPHROPATHY | Jan 20, 2019 | Abandoned |
Array
(
[id] => 16491205
[patent_doc_number] => 10857223
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-08
[patent_title] => Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
[patent_app_type] => utility
[patent_app_number] => 16/252108
[patent_app_country] => US
[patent_app_date] => 2019-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 26
[patent_no_of_words] => 22445
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16252108
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/252108 | Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection | Jan 17, 2019 | Issued |
Array
(
[id] => 16786110
[patent_doc_number] => 10988522
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-27
[patent_title] => Proteolically resistant cyclotides with angiotensin 1-7 like activity
[patent_app_type] => utility
[patent_app_number] => 16/232985
[patent_app_country] => US
[patent_app_date] => 2018-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 9
[patent_no_of_words] => 18510
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16232985
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/232985 | Proteolically resistant cyclotides with angiotensin 1-7 like activity | Dec 25, 2018 | Issued |
Array
(
[id] => 16557191
[patent_doc_number] => 20210002339
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-07
[patent_title] => PEPTIDE AND PHARMACEUTICAL COMPOSITIONS OF SAME FOR USE AS AN ANTIMICROBIAL AND IN CANCER TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/955370
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955370
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955370 | Peptide and pharmaceutical compositions of same for use as an antimicrobial and in cancer treatment | Dec 20, 2018 | Issued |
Array
(
[id] => 14716347
[patent_doc_number] => 20190249237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-15
[patent_title] => MODIFIED BIOTIN-BINDING PROTEINS FOR IMMOBILIZATION
[patent_app_type] => utility
[patent_app_number] => 16/230480
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230480
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/230480 | Modified biotin-binding proteins for immobilization | Dec 20, 2018 | Issued |
Array
(
[id] => 17541009
[patent_doc_number] => 11306119
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-19
[patent_title] => Peptide bound to PD-L1 and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/772809
[patent_app_country] => US
[patent_app_date] => 2018-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 7680
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772809
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/772809 | Peptide bound to PD-L1 and use thereof | Dec 16, 2018 | Issued |
Array
(
[id] => 18716541
[patent_doc_number] => 11793864
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Use of serine protease inhibitors in the treatment of skin diseases
[patent_app_type] => utility
[patent_app_number] => 16/217957
[patent_app_country] => US
[patent_app_date] => 2018-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 23506
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217957
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/217957 | Use of serine protease inhibitors in the treatment of skin diseases | Dec 11, 2018 | Issued |
Array
(
[id] => 15038543
[patent_doc_number] => 20190330276
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => HYALURONIC ACID-BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION, AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/213885
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213885
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/213885 | HYALURONIC ACID-BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION, AND METHODS OF USE | Dec 6, 2018 | Abandoned |
Array
(
[id] => 17649682
[patent_doc_number] => 11352396
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-07
[patent_title] => Antimicrobial peptides and methods of using same
[patent_app_type] => utility
[patent_app_number] => 16/769025
[patent_app_country] => US
[patent_app_date] => 2018-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 7594
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 219
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769025
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/769025 | Antimicrobial peptides and methods of using same | Dec 4, 2018 | Issued |
Array
(
[id] => 17727751
[patent_doc_number] => 11384126
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => Compositions and methods for inhibiting DHHC-type palmitoyltransferases for cancer treatment
[patent_app_type] => utility
[patent_app_number] => 16/766942
[patent_app_country] => US
[patent_app_date] => 2018-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 72
[patent_figures_cnt] => 72
[patent_no_of_words] => 33437
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16766942
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/766942 | Compositions and methods for inhibiting DHHC-type palmitoyltransferases for cancer treatment | Nov 29, 2018 | Issued |
Array
(
[id] => 17490445
[patent_doc_number] => 11279734
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-22
[patent_title] => Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
[patent_app_type] => utility
[patent_app_number] => 16/206944
[patent_app_country] => US
[patent_app_date] => 2018-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 114
[patent_figures_cnt] => 175
[patent_no_of_words] => 46961
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16206944
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/206944 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | Nov 29, 2018 | Issued |
Array
(
[id] => 17490445
[patent_doc_number] => 11279734
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-22
[patent_title] => Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
[patent_app_type] => utility
[patent_app_number] => 16/206944
[patent_app_country] => US
[patent_app_date] => 2018-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 114
[patent_figures_cnt] => 175
[patent_no_of_words] => 46961
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16206944
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/206944 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | Nov 29, 2018 | Issued |
Array
(
[id] => 16437085
[patent_doc_number] => 20200354411
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => Chimeric Molecule for Targeting c-Myc in Cells
[patent_app_type] => utility
[patent_app_number] => 16/760060
[patent_app_country] => US
[patent_app_date] => 2018-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9765
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760060
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/760060 | Chimeric Molecule for Targeting c-Myc in Cells | Nov 28, 2018 | Abandoned |
Array
(
[id] => 18028938
[patent_doc_number] => 11512111
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Yeats inhibitors and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/767434
[patent_app_country] => US
[patent_app_date] => 2018-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 57
[patent_no_of_words] => 40431
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767434
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/767434 | Yeats inhibitors and methods of use thereof | Nov 25, 2018 | Issued |
Array
(
[id] => 16435727
[patent_doc_number] => 20200353052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => COMPOSITION FOR PROMOTING GOBLET CELL PROLIFERATION OR MUCIN SECRETION COMPRISING THYMOSIN BETA 4 OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 16/765929
[patent_app_country] => US
[patent_app_date] => 2018-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16765929
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/765929 | COMPOSITION FOR PROMOTING GOBLET CELL PROLIFERATION OR MUCIN SECRETION COMPRISING THYMOSIN BETA 4 OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT | Nov 22, 2018 | Abandoned |
Array
(
[id] => 14564097
[patent_doc_number] => 20190209655
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-11
[patent_title] => Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof
[patent_app_type] => utility
[patent_app_number] => 16/195184
[patent_app_country] => US
[patent_app_date] => 2018-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16195184
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/195184 | Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof | Nov 18, 2018 | Issued |
Array
(
[id] => 14864939
[patent_doc_number] => 20190282711
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => TARGETING PEPTIDES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/188881
[patent_app_country] => US
[patent_app_date] => 2018-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14065
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16188881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/188881 | Targeting peptides and methods of use | Nov 12, 2018 | Issued |
Array
(
[id] => 14564217
[patent_doc_number] => 20190209715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-11
[patent_title] => Plectin-1 Targeted Agents for Detection and Treatment of Pancreatic Ductal Adenocarcinoma
[patent_app_type] => utility
[patent_app_number] => 16/186078
[patent_app_country] => US
[patent_app_date] => 2018-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26592
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16186078
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/186078 | Plectin-1 Targeted Agents for Detection and Treatment of Pancreatic Ductal Adenocarcinoma | Nov 8, 2018 | Abandoned |